Navigation Links
LeMaitre Vascular to Participate at Canaccord Adams Inaugural Cardiovascular Conference
Date:11/7/2007

BURLINGTON, Mass., Nov. 7 /PRNewswire-FirstCall/ -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), which develops, manufactures, and markets medical devices and implants for the treatment of peripheral vascular disease, is scheduled to participate at the Canaccord Adams inaugural Cardiovascular Conference on Tuesday, November 13, 2007, in New York City, NY at the Waldorf-Astoria Hotel.

David B. Roberts, President of LeMaitre Vascular, will provide an update on the company at 3:45 pm Eastern Standard Time.

A live audio webcast of the presentation will be available via the Internet at http://www.lemaitre.com/investor and will be available for replay for 30 days.

About LeMaitre Vascular

LeMaitre Vascular, Inc. develops, manufactures and markets medical devices and implants for the treatment of peripheral vascular disease. The Company's principal executive offices are located at 63 Second Avenue, Burlington, Massachusetts 01803. Additional information can be found at http://www.lemaitre.com.


'/>"/>
SOURCE LeMaitre Vascular, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. LeMaitre Vascular to Start Italian Sales Force
2. LeMaitre Vascular to Participate at CIBC 18th Annual Healthcare Conference
3. LeMaitre Vascular Reports Q3 2007 Revenue of $10.1 Million, a 19% Increase
4. Antioxidants show no clear benefit against cardiovascular events, death in high-risk women
5. Waist-to-hip ratio may better predict cardiovascular risk than body mass index
6. Pot bellies linked to early signs of cardiovascular disease
7. Air pollution linked to cardiovascular risk indices in healthy young adults
8. Environmental stress probed in cardiovascular disease, diabetes
9. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
10. American Heart Association Enhances eLearning for Emergency Cardiovascular Care (ECC)
11. Researchers provide genetic associations from a genome-wide scan for cardiovascular disease traits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... 25, 2016 , ... TransactRx announces the release of enhanced ... service claims by Pharmacy Benefit Managers that were submitted by Retail Clinics and ... Cross Benefit Clearinghouse receives standard professional medical claims submitted from the retail clinic’s ...
(Date:5/25/2016)... ... May 25, 2016 , ... The University of San Francisco ... Professions. She will lead a team of more than 100 full-time faculty and staff, ... role as dean in late August. , Baker comes to USF from the University ...
(Date:5/25/2016)... FLA (PRWEB) , ... May 25, 2016 , ... ... technology to help turn back the hands of time of female aging. The ... and childbirth. Women with symptoms such as leakage, laxity, itchiness and pain have ...
(Date:5/25/2016)... Pine Brook, NJ (PRWEB) , ... May 25, 2016 , ... ... at the 2016 Annual COVD Meeting for their work on visual evoked potential and ... , summarizes recent studies that used the Diopsys® NOVA™ ERG and VEP Vision ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... ... builder, has announced that it will join America's leading engineers at the American ... held at the Georgia World Congress Center. , Engineers, speakers and exhibitors ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... , May 23, 2016 The World Health Organization ... device to include adolescents aged 13 years, and above. ... be offered for adult and adolescent males in the 14 ... . PrePex was the first male circumcision device to receive ... CEO, Eddy Horowitz said: " The expanded ...
(Date:5/23/2016)... 2016 Gamida Cell, a leader ... cancer and orphan genetic diseases, announced today it has ... from the Israel Innovation Authority (formerly the Office of ... and Industry. The mission of the Israel Innovation Authority ... including science and technology, while stimulating economic growth. ...
(Date:5/22/2016)... , May 23, 2016 ... develop its anti-fibrotic and anti-inflammatory compound DS102 in ... as in non-alcoholic steatohepatitis (NASH) patients. ... significantly sequestered in lung tissue and has bronchodilatory, ... after oral administration. The Company will publish further ...
Breaking Medicine Technology: